108 related articles for article (PubMed ID: 30079960)
21. Genetic variants in DNA repair pathways are not associated with disease progression among multiple myeloma patients.
Thyagarajan B; Arora M; Guan W; Barcelo H; Jackson S; Kumar S; Gertz M
Leuk Res; 2013 Nov; 37(11):1527-31. PubMed ID: 24129343
[TBL] [Abstract][Full Text] [Related]
22. Interactions between SNPs affecting inflammatory response genes are associated with multiple myeloma disease risk and survival.
Nielsen KR; Rodrigo-Domingo M; Steffensen R; Baech J; Bergkvist KS; Oosterhof L; Schmitz A; Bødker JS; Johansen P; Vogel U; Vangsted A; Dybkær K; Bøgsted M; Johnsen HE
Leuk Lymphoma; 2017 Nov; 58(11):2695-2704. PubMed ID: 28393658
[TBL] [Abstract][Full Text] [Related]
23. Vascular endothelial growth factor (VEGF) gene polymorphisms may influence the efficacy of thalidomide in multiple myeloma.
Andersen NF; Vogel U; Klausen TW; Gimsing P; Gregersen H; Abildgaard N; Vangsted AJ
Int J Cancer; 2012 Sep; 131(5):E636-42. PubMed ID: 22139971
[TBL] [Abstract][Full Text] [Related]
24. Polymorphisms of Genes Encoding Multidrug Resistance Proteins as a Predictive Factor for Second-Line Docetaxel Therapy in Advanced Non-small Cell Lung Cancer.
Szczyrek M; Mlak R; Krawczyk P; Wojas-Krawczyk K; Powrózek T; Szudy-Szczyrek A; Zwolak A; Daniluk J; Milanowski J
Pathol Oncol Res; 2017 Jul; 23(3):607-614. PubMed ID: 27988838
[TBL] [Abstract][Full Text] [Related]
25. Influence of ABCC2, SLCO1B1, and ABCG2 polymorphisms on the pharmacokinetics of olmesartan.
Kim CO; Cho SK; Oh ES; Park MS; Chung JY
J Cardiovasc Pharmacol; 2012 Jul; 60(1):49-54. PubMed ID: 22494992
[TBL] [Abstract][Full Text] [Related]
26. FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy.
Bhatnagar V; Gormley NJ; Luo L; Shen YL; Sridhara R; Subramaniam S; Shen G; Ma L; Shord S; Goldberg KB; Farrell AT; McKee AE; Pazdur R
Oncologist; 2017 Nov; 22(11):1347-1353. PubMed ID: 28904172
[TBL] [Abstract][Full Text] [Related]
27. Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia.
Zgheib NK; Akra-Ismail M; Aridi C; Mahfouz R; Abboud MR; Solh H; Muwakkit SA
Pharmacogenet Genomics; 2014 Aug; 24(8):387-96. PubMed ID: 25007187
[TBL] [Abstract][Full Text] [Related]
28. Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma.
van de Donk NWCJ; Casneuf T; Di Cara A; Parren PW; Zweegman S; van Kessel B; Lokhorst HM; Usmani SZ; Lonial S; Richardson PG; Chiu C; Mutis T; Nijhof IS; Sasser AK
Br J Haematol; 2019 Feb; 184(3):475-479. PubMed ID: 29411874
[No Abstract] [Full Text] [Related]
29. Characterization of the breast cancer resistance protein (BCRP/ABCG2) in clear cell renal cell carcinoma.
Reustle A; Fisel P; Renner O; Büttner F; Winter S; Rausch S; Kruck S; Nies AT; Hennenlotter J; Scharpf M; Fend F; Stenzl A; Bedke J; Schwab M; Schaeffeler E
Int J Cancer; 2018 Dec; 143(12):3181-3193. PubMed ID: 30070687
[TBL] [Abstract][Full Text] [Related]
30. Lack of association between ABCC2 gene variants and treatment response in epilepsy.
Hilger E; Reinthaler EM; Stogmann E; Hotzy C; Pataraia E; Baumgartner C; Zimprich A; Zimprich F
Pharmacogenomics; 2012 Jan; 13(2):185-90. PubMed ID: 22256867
[TBL] [Abstract][Full Text] [Related]
31. Drug metabolism and clearance system in tumor cells of patients with multiple myeloma.
Hassen W; Kassambara A; Reme T; Sahota S; Seckinger A; Vincent L; Cartron G; Moreaux J; Hose D; Klein B
Oncotarget; 2015 Mar; 6(8):6431-47. PubMed ID: 25669983
[TBL] [Abstract][Full Text] [Related]
32. Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing.
Ruiz-Heredia Y; Sánchez-Vega B; Onecha E; Barrio S; Alonso R; Martínez-Ávila JC; Cuenca I; Agirre X; Braggio E; Hernández MT; Martínez R; Rosiñol L; Gutierrez N; Martin-Ramos M; Ocio EM; Echeveste MA; de Oteyza JP; Oriol A; Bargay J; Gironella M; Ayala R; Bladé J; Mateos MV; Kortum KM; Stewart K; García-Sanz R; Miguel JS; Lahuerta JJ; Martinez-Lopez J
Haematologica; 2018 Nov; 103(11):e544-e548. PubMed ID: 29954938
[No Abstract] [Full Text] [Related]
33. CTLA-4 polymorphisms are associated with treatment outcomes of patients with multiple myeloma receiving bortezomib-based regimens.
Qin XY; Lu J; Li GX; Wen L; Liu Y; Xu LP; Chang YJ; Liu KY; Jiang ZF; Huang XJ
Ann Hematol; 2018 Mar; 97(3):485-495. PubMed ID: 29264740
[TBL] [Abstract][Full Text] [Related]
34. Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study.
Campa D; Martino A; Macauda A; Dudziński M; Suska A; Druzd-Sitek A; Raab MS; Moreno V; Huhn S; Butrym A; Sainz J; Szombath G; Rymko M; Marques H; Lesueur F; Vangsted AJ; Vogel U; Kruszewski M; Subocz E; Buda G; Iskierka-Jażdżewska E; Ríos R; Merz M; Schöttker B; Mazur G; Perrial E; Martinez-Lopez J; Butterbach K; García Sanz R; Goldschmidt H; Brenner H; Jamroziak K; Reis RM; Kadar K; Dumontet C; Wątek M; Haastrup EK; Helbig G; Jurczyszyn A; Jerez A; Varkonyi J; Barington T; Grzasko N; Zaucha JM; Andersen V; Zawirska D; Canzian F
Leuk Lymphoma; 2019 Jul; 60(7):1803-1811. PubMed ID: 30633655
[TBL] [Abstract][Full Text] [Related]
35. MDR1 polymorphism influences the outcome of multiple myeloma patients.
Buda G; Maggini V; Galimberti S; Martino A; Giuliani N; Morabito F; Genestreti G; Iacopino P; Rizzoli V; Barale R; Rossi AM; Petrini M
Br J Haematol; 2007 Jun; 137(5):454-6. PubMed ID: 17488488
[TBL] [Abstract][Full Text] [Related]
36. [Correlation of metastasis-free survival in patients with breast cancer and changes in the direction of expression of multidrug resistance genes during neoadjuvant chemotherapy].
Litviakov NV; Garbukov EIu; Slonimskaia EM; Tsyganov MM; Denisov EV; Vtorushin SV; Khristenko KIu; Zav'ialova MV; Cherdyntseva NV
Vopr Onkol; 2013; 59(3):334-40. PubMed ID: 23909034
[TBL] [Abstract][Full Text] [Related]
37. Influence of drug-transporter polymorphisms on the pharmacokinetics of fexofenadine enantiomers.
Akamine Y; Miura M; Sunagawa S; Kagaya H; Yasui-Furukori N; Uno T
Xenobiotica; 2010 Nov; 40(11):782-9. PubMed ID: 20839930
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.
Broyl A; Corthals SL; Jongen JL; van der Holt B; Kuiper R; de Knegt Y; van Duin M; el Jarari L; Bertsch U; Lokhorst HM; Durie BG; Goldschmidt H; Sonneveld P
Lancet Oncol; 2010 Nov; 11(11):1057-65. PubMed ID: 20864405
[TBL] [Abstract][Full Text] [Related]
39. Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma.
Johnson DC; Weinhold N; Mitchell JS; Chen B; Kaiser M; Begum DB; Hillengass J; Bertsch U; Gregory WA; Cairns D; Jackson GH; Försti A; Nickel J; Hoffmann P; Nöethen MM; Stephens OW; Barlogie B; Davis FE; Hemminki K; Goldschmidt H; Houlston RS; Morgan GJ
Nat Commun; 2016 Jan; 7():10290. PubMed ID: 26743840
[TBL] [Abstract][Full Text] [Related]
40. ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome.
Surowiak P; Materna V; Kaplenko I; Spaczynski M; Dolinska-Krajewska B; Gebarowska E; Dietel M; Zabel M; Lage H
Clin Cancer Res; 2006 Dec; 12(23):7149-58. PubMed ID: 17145840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
